drugset / Trial / NCT01463982
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine
Timeline
- Start
- 2010-12
- Primary completion
- 2012-04
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 800 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | HM30181AK | Unknown | 15 mg | Oral |
| Subject | Irinotecan | Small molecule | 10 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 20 mg/m2 | Oral |